Journal of gastrointestinal cancer · 2017
The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hernando-Cubero Jorge, Matos-García Ignacio, Alonso-Orduña Vicente, Capdevila Jaume
Аннотация
PURPOSE: Gastrointestinal tumours are one of the most common types of cancer. Therapeutic options include surgery, radiotherapy, local ablation techniques, targeted agents, and chemotherapy. Fluoroprimidines are one of the most active drug families in digestive tumours and remains the cornerstone of the most commonly used chemotherapy schemes.
METHODS: We review the molecular basis of thymidylate synthase inhibition and the mechanisms of action of 5-fluorouracil, next generation oral fluoropyrimidines (capecitabine, tegafur and the latest S-1 and TAS-102) and antifolates.
RESULTS: In addition, mechanisms and biomarkers of resistance and toxicity are explored. Finally, new fluoropyrimidines development and clinical trials ongoing in digestive tumours are reviewed.
CONCLUSIONS: Further research is necessary to avoid resistance mechanisms, improve clinical outcomes and continue reducing toxicities. Until new drugs become available, the optimization of current therapies should be a priority.
METHODS: We review the molecular basis of thymidylate synthase inhibition and the mechanisms of action of 5-fluorouracil, next generation oral fluoropyrimidines (capecitabine, tegafur and the latest S-1 and TAS-102) and antifolates.
RESULTS: In addition, mechanisms and biomarkers of resistance and toxicity are explored. Finally, new fluoropyrimidines development and clinical trials ongoing in digestive tumours are reviewed.
CONCLUSIONS: Further research is necessary to avoid resistance mechanisms, improve clinical outcomes and continue reducing toxicities. Until new drugs become available, the optimization of current therapies should be a priority.
Предметные рубрики MeSH
Administration, OralAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorClinical Trials as TopicDihydrouracil Dehydrogenase (NADP)Drug CombinationsDrug Resistance, NeoplasmDrug SynergismFluorouracilFolic Acid AntagonistsGastrointestinal NeoplasmsHumansMolecular Targeted TherapyPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPyrrolidinesThymidine PhosphorylaseThymidylate SynthaseThymineTrifluridineUracil